Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study.
作者信息
van Beers Eduard J, van Straaten Stephanie, Morton D Holmes, Barcellini Wilma, Eber Stefan W, Glader Bertil, Yaish Hassan M, Chonat Satheesh, Kwiatkowski Janet L, Rothman Jennifer A, Sharma Mukta, Neufeld Ellis J, Sheth Sujit, Despotovic Jenny M, Kollmar Nina, Pospíšilová Dagmar, Knoll Christine M, Kuo Kevin, Pastore Yves D, Thompson Alexis A, Newburger Peter E, Ravindranath Yaddanapudi, Wang Winfred C, Wlodarski Marcin W, Wang Heng, Holzhauer Susanne, Breakey Vicky R, Verhovsek Madeleine, Kunz Joachim, McNaull Melissa A, Rose Melissa J, Bradeen Heather A, Addonizio Kathryn, Li Anran, Al-Sayegh Hasan, London Wendy B, Grace Rachael F
机构信息
Van Creveldkliniek, University Medical Centre Utrecht, University of Utrecht, the Netherlands.
Central Pennsylvania Clinic for Special Children & Adults, Belleville, PA, USA Lancaster General Hospital, Lancaster, PA, USA.
出版信息
Haematologica. 2019 Feb;104(2):e51-e53. doi: 10.3324/haematol.2018.196295. Epub 2018 Sep 13.
Abstract
摘要
相似文献
1
Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study.
Haematologica. 2019 Feb;104(2):e51-e53. doi: 10.3324/haematol.2018.196295. Epub 2018 Sep 13.
2
Unexpectedly high but still asymptomatic iron overload in a patient with pyruvate kinase deficiency.
Hematol J. 2004;5(6):543-5. doi: 10.1038/sj.thj.6200556.
3
Pyruvate kinase deficiency in pregnancy complicated by iron overload.
BJOG. 2002 Jul;109(7):844-6. doi: 10.1111/j.1471-0528.2002.01083.x.
4
Iron status in patients with pyruvate kinase deficiency: neonatal hyperferritinaemia associated with a novel frameshift deletion in the PKLR gene (p.Arg518fs), and low hepcidin to ferritin ratios.
Br J Haematol. 2014 May;165(4):556-63. doi: 10.1111/bjh.12779. Epub 2014 Feb 18.
5
Iron status and HFE genotype in erythrocyte pyruvate kinase deficiency: study of Italian cases.
Blood Cells Mol Dis. 2001 May-Jun;27(3):653-61. doi: 10.1006/bcmd.2001.0433.
6
How we manage patients with pyruvate kinase deficiency.
Br J Haematol. 2019 Mar;184(5):721-734. doi: 10.1111/bjh.15758. Epub 2019 Jan 25.
7
The use of MRI to monitor iron overload in SCD.
Blood Cells Mol Dis. 2017 Sep;67:120-125. doi: 10.1016/j.bcmd.2017.09.002. Epub 2017 Sep 6.
8
Iron Chelation Therapy as a Modality of Management.
Hematol Oncol Clin North Am. 2018 Apr;32(2):261-275. doi: 10.1016/j.hoc.2017.12.002. Epub 2018 Jan 17.
9
The dangers of iron overload in pyruvate kinase deficiency.
Br J Haematol. 2003 Mar;120(6):1090-1. doi: 10.1046/j.1365-2141.2003.04208_2.x.
10
Pancreatic iron overload by T2* MRI in a large cohort of well treated thalassemia major patients: can it tell us heart iron distribution and function?
Am J Hematol. 2015 Sep;90(9):E189-90. doi: 10.1002/ajh.24081.
引用本文的文献
1
Hereditary disorders of ineffective erythropoiesis.
Blood Cells Mol Dis. 2025 Mar;111:102910. doi: 10.1016/j.bcmd.2025.102910. Epub 2025 Feb 7.
2
Efficacy and Safety of Mitapivat in Pyruvate Kinase Deficiency: A Systematic Review and Meta-analysis of Clinical Trials.
Indian J Hematol Blood Transfus. 2025 Jan;41(1):112-120. doi: 10.1007/s12288-024-01830-x. Epub 2024 Aug 6.
3
Flawed Value Assessment of Mitapivat to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency.
Am J Ther. 2025;32(1):e35-e36. doi: 10.1097/MJT.0000000000001797. Epub 2024 Jul 23.
4
Clinical and Demographic Characteristics of Pyruvate Kinase Deficiency Patients: A Comprehensive Case Series Analysis.
Cureus. 2024 May 10;16(5):e60035. doi: 10.7759/cureus.60035. eCollection 2024 May.
5
Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency.
Blood Adv. 2024 May 28;8(10):2433-2441. doi: 10.1182/bloodadvances.2023011743.
6
Pyruvate kinase activators for treatment of pyruvate kinase deficiency.
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):97-106. doi: 10.1182/hematology.2023000466.
7
Psychometric validation of the Pyruvate Kinase Deficiency Diary and Pyruvate Kinase Deficiency Impact Assessment in adults in the phase 3 ACTIVATE trial.
J Patient Rep Outcomes. 2023 Nov 9;7(1):112. doi: 10.1186/s41687-023-00650-3.
8
Clinical outcome and genotype analysis of four Chinese children with pyruvate kinase deficiency.
Mol Genet Genomic Med. 2023 Nov;11(11):e2239. doi: 10.1002/mgg3.2239. Epub 2023 Jul 19.
9
The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study design.
BMJ Open. 2023 Mar 23;13(3):e063605. doi: 10.1136/bmjopen-2022-063605.
10
Updates and advances in pyruvate kinase deficiency.
Trends Mol Med. 2023 May;29(5):406-418. doi: 10.1016/j.molmed.2023.02.005. Epub 2023 Mar 17.
本文引用的文献
1
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.
Blood. 2018 May 17;131(20):2183-2192. doi: 10.1182/blood-2017-10-810796. Epub 2018 Mar 16.
2
Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions.
J Blood Med. 2015 Jun 17;6:197-209. doi: 10.2147/JBM.S72463. eCollection 2015.
3
Erythrocyte pyruvate kinase deficiency: 2015 status report.
Am J Hematol. 2015 Sep;90(9):825-30. doi: 10.1002/ajh.24088. Epub 2015 Aug 14.
4
Iron-chelating therapy for transfusional iron overload.
N Engl J Med. 2011 Jan 13;364(2):146-56. doi: 10.1056/NEJMct1004810.
5
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.
Haematologica. 2010 Apr;95(4):557-66. doi: 10.3324/haematol.2009.014696. Epub 2009 Nov 30.
6
Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Haematologica. 2007 May;92(5):583-8. doi: 10.3324/haematol.10842.
Zotero 插件